Cargando…
COVID-19 vaccine candidates and vaccine development platforms available worldwide
The pandemic caused by the worldwide spread of the coronavirus, which first appeared in 2019, has been named coronavirus disease 19 (COVID-19). More than 4.5 million deaths have been recorded due to the pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), according to the...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Xi'an Jiaotong University
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8437828/ https://www.ncbi.nlm.nih.gov/pubmed/34540318 http://dx.doi.org/10.1016/j.jpha.2021.09.004 |
_version_ | 1783752237285113856 |
---|---|
author | Duman, Nilgun ALzaidi, Zahraa Aynekin, Busra Taskin, Duygu Demirors, Busra Yildirim, Abdulbaki Sahin, Izem Olcay Bilgili, Faik Turanli, Eda Tahir Beccari, Tommaso Bertelli, Matteo Dundar, Munis |
author_facet | Duman, Nilgun ALzaidi, Zahraa Aynekin, Busra Taskin, Duygu Demirors, Busra Yildirim, Abdulbaki Sahin, Izem Olcay Bilgili, Faik Turanli, Eda Tahir Beccari, Tommaso Bertelli, Matteo Dundar, Munis |
author_sort | Duman, Nilgun |
collection | PubMed |
description | The pandemic caused by the worldwide spread of the coronavirus, which first appeared in 2019, has been named coronavirus disease 19 (COVID-19). More than 4.5 million deaths have been recorded due to the pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), according to the World Health Organization. COVID-19 Dashboard in September 2021. Apart from the wildtype, other variations have been successfully transmitted early in the outbreak although they were not discovered until March 2020. Modifications in the SARS-CoV-2 genetic material, such as mutation and recombination, have the ability to modify the viral life span, along with transitivity, cellular tropism, and symptom severity. Several processes are involved in introducing novel vaccines to the population, including vaccine manufacturing, preclinical studies, Food and Drug Administration permission or certification, processing, and marketing. COVID-19 vaccine candidates have been developed by a number of public and private groups employing a variety of strategies, such as RNA, DNA, protein, and viral vectored vaccines. This comprehensive review, which included the most subsequent evidence on unique features of SARS-CoV-2 and the associated morbidity and mortality, was carried out using a systematic search of recent online databases in order to generate useful knowledge about the COVID-19 updated versions and their consequences on the disease symptoms and vaccine development. |
format | Online Article Text |
id | pubmed-8437828 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Xi'an Jiaotong University |
record_format | MEDLINE/PubMed |
spelling | pubmed-84378282021-09-14 COVID-19 vaccine candidates and vaccine development platforms available worldwide Duman, Nilgun ALzaidi, Zahraa Aynekin, Busra Taskin, Duygu Demirors, Busra Yildirim, Abdulbaki Sahin, Izem Olcay Bilgili, Faik Turanli, Eda Tahir Beccari, Tommaso Bertelli, Matteo Dundar, Munis J Pharm Anal Review Paper The pandemic caused by the worldwide spread of the coronavirus, which first appeared in 2019, has been named coronavirus disease 19 (COVID-19). More than 4.5 million deaths have been recorded due to the pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), according to the World Health Organization. COVID-19 Dashboard in September 2021. Apart from the wildtype, other variations have been successfully transmitted early in the outbreak although they were not discovered until March 2020. Modifications in the SARS-CoV-2 genetic material, such as mutation and recombination, have the ability to modify the viral life span, along with transitivity, cellular tropism, and symptom severity. Several processes are involved in introducing novel vaccines to the population, including vaccine manufacturing, preclinical studies, Food and Drug Administration permission or certification, processing, and marketing. COVID-19 vaccine candidates have been developed by a number of public and private groups employing a variety of strategies, such as RNA, DNA, protein, and viral vectored vaccines. This comprehensive review, which included the most subsequent evidence on unique features of SARS-CoV-2 and the associated morbidity and mortality, was carried out using a systematic search of recent online databases in order to generate useful knowledge about the COVID-19 updated versions and their consequences on the disease symptoms and vaccine development. Xi'an Jiaotong University 2021-12 2021-09-14 /pmc/articles/PMC8437828/ /pubmed/34540318 http://dx.doi.org/10.1016/j.jpha.2021.09.004 Text en © 2021 Xi'an Jiaotong University. Production and hosting by Elsevier B.V. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Review Paper Duman, Nilgun ALzaidi, Zahraa Aynekin, Busra Taskin, Duygu Demirors, Busra Yildirim, Abdulbaki Sahin, Izem Olcay Bilgili, Faik Turanli, Eda Tahir Beccari, Tommaso Bertelli, Matteo Dundar, Munis COVID-19 vaccine candidates and vaccine development platforms available worldwide |
title | COVID-19 vaccine candidates and vaccine development platforms available worldwide |
title_full | COVID-19 vaccine candidates and vaccine development platforms available worldwide |
title_fullStr | COVID-19 vaccine candidates and vaccine development platforms available worldwide |
title_full_unstemmed | COVID-19 vaccine candidates and vaccine development platforms available worldwide |
title_short | COVID-19 vaccine candidates and vaccine development platforms available worldwide |
title_sort | covid-19 vaccine candidates and vaccine development platforms available worldwide |
topic | Review Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8437828/ https://www.ncbi.nlm.nih.gov/pubmed/34540318 http://dx.doi.org/10.1016/j.jpha.2021.09.004 |
work_keys_str_mv | AT dumannilgun covid19vaccinecandidatesandvaccinedevelopmentplatformsavailableworldwide AT alzaidizahraa covid19vaccinecandidatesandvaccinedevelopmentplatformsavailableworldwide AT aynekinbusra covid19vaccinecandidatesandvaccinedevelopmentplatformsavailableworldwide AT taskinduygu covid19vaccinecandidatesandvaccinedevelopmentplatformsavailableworldwide AT demirorsbusra covid19vaccinecandidatesandvaccinedevelopmentplatformsavailableworldwide AT yildirimabdulbaki covid19vaccinecandidatesandvaccinedevelopmentplatformsavailableworldwide AT sahinizemolcay covid19vaccinecandidatesandvaccinedevelopmentplatformsavailableworldwide AT bilgilifaik covid19vaccinecandidatesandvaccinedevelopmentplatformsavailableworldwide AT turanliedatahir covid19vaccinecandidatesandvaccinedevelopmentplatformsavailableworldwide AT beccaritommaso covid19vaccinecandidatesandvaccinedevelopmentplatformsavailableworldwide AT bertellimatteo covid19vaccinecandidatesandvaccinedevelopmentplatformsavailableworldwide AT dundarmunis covid19vaccinecandidatesandvaccinedevelopmentplatformsavailableworldwide |